Please assess the completion status of the following clinical trial:

Trial Title: Leflunomide for Maintenance of Remission in IgG4 Related Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 80 years.~2. Diagnosis of IgG4-RD according to either Consensus statement on the pathology of IgG4-related disease (for those who have undergone biopsies) or 2011 Comprehensive diagnostic criteria for IgG4-related disease. Both of the two criteria for diagnosis are specified below.~(1)Consensus statement on the pathology of IgG4-related disease~1. Histopathologic features consisting of dense lymphoplasmacytic infiltrate, fibrosis(usually storiform in character)and/or obliterative phlebitis within involved organs.~2. Either an elevated IgG4+/IgG+cell ratio of \>40% within the affected organs or elevated IgG4-bearing plasma cells per high-power field is necessary. The cut-off number of IgG4-bearing plasma cells per high-power field is different depending upon the types of affected organs and specimens(through surgery or needle puncture biopsy).~(2)2011 Comprehensive diagnostic criteria for IgG4-related disease~1. Clinical examination showing characteristic diffuse/localized swelling or masses in single or multiple organs.~2. Hematological examination shows elevated serum IgG4 concentrations(135 mg/dl).~3. Histopathologic examination shows marked lymphocyte and plasmacyte infiltration and fibrosis or Infiltration of IgG4+ plasma cells(ratio of IgG4+/IgG+ cells \> 40% and \>10 IgG4+ plasma cells/HPF).~   Definite: a + b + c,Probable: a + c,Possible: a + b~4. Excluded from malignant tumors of each organ (e.g. cancer, lymphoma) and similar diseases (e.g. Sjögren's syndrome, primary sclerosing cholangitis, Castleman's disease, secondary retroperitoneal fibrosis, Wegener's granulomatosis, sarcoidosis, Churg-Strauss syndrome) by additional histopathological examination.~5. Even when patients cannot be diagnosed using the Comprehensive diagnostic criteria, they may be diagnosed using organ-specific diagnostic criteria for IgG4-RD, such as Diagnostic criteria for IgG4-Mikulicz's disease.~Exclusion Criteria:~1. Subjects having received steroids or immunosuppressants in recent 3 months will be excluded.~2. Subjects who were hypersensitive to leflunomide will be excluded.~3. ALT and/or AST is more than two folds of the upper limit of relevant reference value at baseline.~4. WBC is less than 3×10\*9/L at baseline.~5. Female patients who are pregnant or breastfeeding.~6. Known significant concurrent medical disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: EXPERIMENTAL): Prednisone mono-therapy
- Prednisone and Leflunomide (Type: EXPERIMENTAL): Prednisone and Leflunomide combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).